

Giant Cell Arteritis Treatment Market Report and Forecast 2024-2032

Market Report | 2024-09-30 | 250 pages | EMR Inc.

AVAILABLE LICENSES:

- Single User License \$4999.00
- Five User License \$5999.00
- Corporate License \$6999.00

Report description:

Giant Cell Arteritis Treatment Market Report and Forecast 2024-2032

The giant cell arteritis treatment market was valued at USD 1.1 billion in 2023, driven by increasing healthcare expenditure across the globe. It is expected to grow at a CAGR of 6.2% during the forecast period of 2024-2032, likely to reach a market value of USD 1.9 billion by 2032.

Giant Cell Arteritis Treatment Market Analysis

Giant Cell Arteritis (GCA), also known as temporal arteritis, is an inflammatory disease affecting the large blood vessels of the scalp, neck, and arms. It is most commonly seen in people over the age of 50, particularly women. The treatment market for GCA has witnessed significant growth due to advancements in medical research and an increasing prevalence of the disease. The market comprises various treatment options, including corticosteroids, immunosuppressive agents, and biologics such as tocilizumab.

Market Drivers

Increasing Prevalence of GCA: The rising incidence of GCA, particularly among the ageing population, is a primary driver for the market. As life expectancy increases, the number of individuals at risk for GCA is expected to grow, thereby driving the demand for effective treatments.

Advancements in Medical Research: Continuous research and development in the field of autoimmune diseases have led to the introduction of new and effective treatment options. The approval of biologics such as tocilizumab has significantly impacted the market by providing alternative treatment options for patients who do not respond to conventional therapies.

Growing Awareness and Diagnosis: Improved awareness and understanding of GCA among healthcare professionals and the public

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

have led to earlier diagnosis and treatment, which is crucial for preventing complications such as vision loss. Early diagnosis increases the demand for treatment options, thereby driving market growth.

Government Initiatives and Funding: Support from government bodies and non-profit organisations in the form of funding and awareness campaigns has further bolstered the market. These initiatives promote research activities and provide better access to healthcare services for patients with GCA.

Challenges

Side Effects of Treatment: The long-term use of corticosteroids, which are the mainstay of GCA treatment, is associated with significant side effects such as osteoporosis, hypertension, and diabetes. These adverse effects can limit patient compliance and pose a challenge to the market.

High Cost of Biologics: While biologics have shown efficacy in treating GCA, their high cost can be a barrier to widespread adoption. The financial burden on healthcare systems and patients can restrict market growth, particularly in developing regions.

Limited Awareness in Developing Regions: In many developing countries, the awareness and diagnosis of GCA remain low. Limited access to healthcare facilities and a lack of specialised medical professionals can hinder the market growth in these regions.

Future Opportunities

Development of New Therapies: Ongoing research and clinical trials are expected to yield new treatment options with fewer side effects and improved efficacy. The development of novel biologics and small molecule inhibitors holds promise for the future of GCA treatment.

Expansion into Emerging Markets: Increasing healthcare infrastructure and awareness in emerging markets present significant growth opportunities. Companies can capitalise on these regions by investing in awareness campaigns and partnerships with local healthcare providers.

Personalised Medicine: Advances in genomics and personalised medicine could lead to more tailored treatment approaches for GCA patients. Understanding the genetic and molecular basis of the disease can help in developing targeted therapies that improve patient outcomes.

Regulatory Approvals and Reimbursements: Obtaining regulatory approvals for new treatments and securing reimbursement from insurance providers can drive market growth. Easier access to effective treatments through insurance coverage can alleviate the financial burden on patients.

Giant Cell Arteritis Treatment Market Trends

The giant cell arteritis (GCA) treatment market is evolving rapidly, driven by advancements in medical research and an increasing understanding of the disease. Emerging trends are shaping the future of GCA treatment, promising improved patient outcomes and enhanced market growth.

Market Trends

Shift Towards Biologics and Targeted Therapies: There is a growing trend towards the use of biologics and targeted therapies in the treatment of GCA. Biologics such as tocilizumab have shown significant efficacy in reducing inflammation and preventing

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

relapses, offering an alternative to traditional corticosteroid treatments. This shift is driven by the need for more effective and safer treatment options with fewer side effects.

Increased Focus on Early Diagnosis and Treatment: Early diagnosis and prompt treatment of GCA are becoming increasingly emphasised in the medical community. Advances in diagnostic tools, such as imaging techniques and biomarker identification, are aiding in the early detection of the disease. This trend is crucial as early intervention can prevent severe complications like vision loss and improve long-term outcomes.

Personalised Medicine Approaches: The adoption of personalised medicine in GCA treatment is on the rise. Understanding the genetic and molecular profiles of patients allows for tailored treatment plans that are more effective and have fewer side effects. This trend is supported by advancements in genomics and biotechnology, enabling more precise and customised therapeutic approaches.

Integration of Digital Health Technologies: Digital health technologies, including telemedicine and wearable devices, are being increasingly integrated into the management of GCA. These technologies facilitate remote monitoring of patients, adherence to treatment plans, and early detection of relapses. The use of digital health tools enhances patient engagement and allows for more efficient and personalised care.

Collaborative Research and Development Efforts: Collaborative efforts between pharmaceutical companies, research institutions, and healthcare providers are driving innovation in GCA treatment. Joint ventures, partnerships, and consortia are pooling resources and expertise to accelerate the development of new therapies and improve existing ones. This trend is fostering a more robust pipeline of potential treatments.

Regulatory Support and Fast-Track Approvals: Regulatory bodies are recognising the need for new and effective GCA treatments, leading to faster approval processes for promising therapies. Initiatives such as orphan drug designations and priority review programmes are helping to expedite the availability of innovative treatments in the market. This regulatory support is crucial for addressing unmet medical needs in GCA.

Expansion of Patient Access Programmes: Pharmaceutical companies are increasingly implementing patient access programmes to make treatments more affordable and accessible. These programmes, including financial assistance and patient support services, aim to reduce the economic burden on patients and ensure they receive necessary treatments. This trend is particularly important in regions with limited healthcare resources.

Growing Awareness and Education Initiatives: Efforts to raise awareness and educate both healthcare professionals and the public about GCA are intensifying. Educational campaigns, professional training, and patient advocacy are playing a key role in improving the understanding of the disease and promoting early diagnosis and treatment. Increased awareness is expected to drive demand for GCA treatments and improve patient outcomes.

Giant Cell Arteritis Treatment Market Segmentation

Market Breakup by Treatment Type

Medication

Corticosteroid Therapy

Immunosuppressive Agents

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Anticoagulants

Monoclonal antibodies

Surgery

The giant cell arteritis (GCA) treatment market, segmented by treatment type, is driven by the increasing prevalence of GCA and advancements in medical research. Medication remains the dominant segment, with corticosteroid therapy being the first line of treatment despite its side effects. Immunosuppressive agents and anticoagulants are gaining traction as adjunct therapies. Monoclonal antibodies, particularly tocilizumab, are emerging as effective alternatives, driving significant market growth. Surgical interventions, though less common, are essential for severe cases. Future growth is anticipated from the development of new biologics and targeted therapies, positioning these segments to propel market expansion during the forecast period.

Market Breakup by Route of Administration

Oral

Intravenous

Subcutaneous

Others

The giant cell arteritis (GCA) treatment market, segmented by route of administration, is driven by the need for effective and convenient treatment options. Oral administration remains the most common route due to its ease of use and patient compliance, particularly for corticosteroids and immunosuppressive agents. Intravenous administration, often used for monoclonal antibodies like tocilizumab, offers rapid and targeted therapeutic effects, driving its demand. Subcutaneous administration is gaining popularity for its convenience and reduced need for hospital visits. Other routes, including topical and intramuscular, are utilised in specific cases. The diversification of administration routes is poised to drive market growth in the forecast period.

Market Breakup by End Use

Hospitals

Clinics

ASCs

Others

The giant cell arteritis (GCA) treatment market, segmented by end use, is primarily driven by the increasing demand for specialised care and advanced treatment options. Hospitals dominate the market due to their comprehensive facilities and capability to handle complex cases, including intravenous and surgical treatments. Clinics provide accessible care for ongoing management and monitoring of GCA, supporting patient adherence to therapy. Ambulatory Surgery Centres (ASCs) offer efficient, cost-effective outpatient surgical interventions. Other settings, such as home care and specialised centres, cater to personalised treatment plans. The expansion of these end-use segments is expected to significantly drive market growth during the forecast

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

period.

Market Breakup by Region

United States

EU-4 and the United Kingdom

Germany

France

Italy

Spain

United Kingdom

Japan

India

The giant cell arteritis (GCA) treatment market, segmented by region, is influenced by varying healthcare infrastructure and prevalence rates. The United States leads the market due to advanced healthcare facilities and significant R&D investments. The EU-4 (Germany, France, Italy, Spain) and the United Kingdom collectively hold substantial market shares, driven by strong healthcare systems and high awareness levels. Japan, with its ageing population, presents a growing market for GCA treatments. India, despite lower awareness, is an emerging market due to improving healthcare access and rising disease incidence. These regions are expected to drive significant market growth during the forecast period, with tailored strategies enhancing regional penetration.

Giant Cell Arteritis Treatment Market Competitive Landscape

The competitive landscape of the giant cell arteritis (GCA) treatment market is characterised by the presence of several key players, including F. Hoffmann-La Roche Ltd., Tianjin Tianyao Pharmaceutical Co., Teva Pharmaceutical Industries Ltd., GlaxoSmithKline, Pfizer Inc., Novartis, AstraZeneca, Merck & Co., Inc., Sanofi S.A., and Astellas Pharma, Inc. Common market activities include mergers and acquisitions to expand product portfolios and enhance market reach. Research initiatives focus on developing novel biologics and targeted therapies. Product introductions aim at offering advanced treatment options with improved efficacy and safety profiles. Partnerships and collaborations are strategic moves to foster innovation and streamline distribution channels, driving market growth and competitive advantage.

?

Key Questions Answered in the Report

What is the current and future performance of the Giant cell arteritis treatment market?

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- What are the main challenges facing the giant cell arteritis treatment market?
- What are the key drivers of the giant cell arteritis treatment market?
- What emerging trends are shaping the future of the giant cell arteritis treatment market?
- What are the primary treatments for giant cell arteritis and their associated side effects?
- Why is intravenous administration preferred for monoclonal antibodies like tocilizumab in GCA treatment?
- Why do the EU-4 and the United Kingdom hold substantial market shares in the GCA treatment market?

Key Benefits for Stakeholders

- The industry report offers a comprehensive quantitative analysis of various market segments, historical and current market trends, market forecasts, and dynamics of the giant cell arteritis treatment market from 2017-2032.
- The research report provides the latest information on the market drivers, challenges, and opportunities in the giant cell arteritis treatment market.
- The study maps the leading, as well as the fastest-growing, regional markets. It further enables stakeholders to identify the key country-level markets within each region.
- Porter's five forces analysis assists stakeholders in assessing the impact of new entrants, competitive rivalry, supplier power, buyer power, and the threat of substitution. It helps stakeholders to analyze the level of competition within the giant cell arteritis treatment industry and its attractiveness.
- The competitive landscape allows stakeholders to understand their competitive environment and provides insight into the current positions of key players in the market.

Table of Contents:

- 1 Preface
 - 1.1 Objectives of the Study
 - 1.2 Key Assumptions
 - 1.3 Report Coverage - Key Segmentation and Scope
 - 1.4 Research Methodology
- 2 Executive Summary
- 3 Giant Cell Arteritis Treatment Market Overview - 8 Major Markets
 - 3.1 Giant Cell Arteritis Treatment Market Historical Value (2017-2023)
 - 3.2 Giant Cell Arteritis Treatment Market Forecast Value (2024-2032)
- 4 Vendor Positioning Analysis
 - 4.1 Key Vendors
 - 4.2 Prospective Leaders
 - 4.3 Niche Leaders

- 4.4□Disruptors
- 5□Giant Cell Arteritis Treatment Overview
- 5.1□Guidelines and Stages
- 5.2□Pathophysiology
- 5.3□Screening and Diagnosis
- 5.4□Treatment Pathway
- 6□Patient Profile
- 6.1□Patient Profile Overview
- 6.2□Patient Psychology and Emotional Impact Factors
- 6.3□Risk Assessment and Treatment Success Rate
- 7□Giant Cell Arteritis Treatment Epidemiology Scenario and Forecast - 8 Major Markets
- 7.1□8MM Epidemiology Scenario Overview (2017-2032)
- 7.1.1□Prevalence, by Country
- 7.1.1.1□U.S.
- 7.1.1.2□U.K.
- 7.1.1.3□EU4
- 7.1.1.4□India
- 7.1.1.5□Japan
- 7.1.2□Mortality, by Country
- 7.1.2.1□U.S.
- 7.1.2.2□U.K.
- 7.1.2.3□EU4
- 7.1.2.4□India
- 7.1.2.5□Japan
- 7.1.3□Treatment seeking rate, by Country
- 7.1.3.1□U.S.
- 7.1.3.2□U.K.
- 7.1.3.3□EU4
- 7.1.3.4□India
- 7.1.3.5□Japan
- 8□Giant Cell Arteritis Treatment Market Landscape - 8 Major Markets
- 8.1□Giant Cell Arteritis Treatment: Developers Landscape
- 8.1.1□Analysis by Year of Establishment
- 8.1.2□Analysis by Company Size
- 8.1.3□Analysis by Region
- 8.2□Giant Cell Arteritis Treatment: Product Landscape
- 8.2.1□Analysis by Treatment Type
- 8.2.2□Analysis by Route of Administration
- 9□Giant Cell Arteritis Treatment Challenges and Unmet Needs
- 9.1□Treatment Pathway Challenges
- 9.2□Compliance and Drop-Out Analysis
- 9.3□Awareness and Prevention Gaps
- 10□Cost of Treatment
- 11□Giant Cell Arteritis Treatment Market Dynamics
- 11.1□Market Drivers and Constraints
- 11.2□SWOT Analysis
- 11.2.1□Strengths

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 11.2.2 Weaknesses
- 11.2.3 Opportunities
- 11.2.4 Threats
- 11.3 PESTEL Analysis
 - 11.3.1 Political
 - 11.3.2 Economic
 - 11.3.3 Social
 - 11.3.4 Technological
 - 11.3.5 Legal
 - 11.3.6 Environment
- 11.4 Porter's Five Forces Model
 - 11.4.1 Bargaining Power of Suppliers
 - 11.4.2 Bargaining Power of Buyers
 - 11.4.3 Threat of New Entrants
 - 11.4.4 Threat of Substitutes
 - 11.4.5 Degree of Rivalry
- 11.5 Key Demand Indicators
- 11.6 Key Price Indicators
- 11.7 Industry Events, Initiatives, and Trends
- 11.8 Value Chain Analysis
- 12 Giant Cell Arteritis Treatment Market Segmentation (2017-2032) - 8 Major Markets
 - 12.1 Giant Cell Arteritis Treatment Market (2017-2032) by Treatment Type
 - 12.1.1 Market Overview
 - 12.1.2 Medication
 - 12.1.2.1 Corticosteroid Therapy
 - 12.1.2.2 Immunosuppressive Agents
 - 12.1.2.3 Anticoagulants
 - 12.1.2.4 Monoclonal antibodies
 - 12.1.3 Surgery
 - 12.2 Giant Cell Arteritis Treatment Market (2017-2032) by Route of Administration
 - 12.2.1 Market Overview
 - 12.2.2 Oral
 - 12.2.3 Intravenous
 - 12.2.4 Subcutaneous
 - 12.2.5 Others
 - 12.3 Giant Cell Arteritis Treatment Market (2017-2032) by End Use
 - 12.3.1 Market Overview
 - 12.3.2 Hospitals
 - 12.3.3 Clinics
 - 12.3.4 ASC's
 - 12.3.5 Others
 - 12.4 Giant Cell Arteritis Treatment Market (2017-2032) by Region
 - 12.4.1 Market Overview
 - 12.4.2 United States
 - 12.4.3 EU-4 and the United Kingdom
 - 12.4.3.1 Germany
 - 12.4.3.2 France

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 12.4.3.3 Italy
- 12.4.3.4 Spain
- 12.4.3.5 United Kingdom
- 12.4.4 Japan
- 12.4.5 India
- 13 United States Giant Cell Arteritis Treatment Market (2017-2032)
- 13.1 United States Giant Cell Arteritis Treatment Market Historical Value (2017-2023)
- 13.2 United States Giant Cell Arteritis Treatment Market Forecast Value (2024-2032)
- 13.3 United States Giant Cell Arteritis Treatment Market (2017-2032) by Treatment Type
- 13.3.1 Market Overview
- 13.3.2 Medication
- 13.3.2.1 Corticosteroid Therapy
- 13.3.2.2 Immunosuppressive Agents
- 13.3.2.3 Anticoagulants
- 13.3.2.4 Monoclonal antibodies
- 13.3.3 Surgery
- 13.4 United States Giant Cell Arteritis Treatment Market (2017-2032) by Route of Administration
- 13.4.1 Market Overview
- 13.4.2 Oral
- 13.4.3 Intravenous
- 13.4.4 Subcutaneous
- 13.4.5 Others
- 13.5 United States Giant Cell Arteritis Treatment Market (2017-2032) by End Use
- 13.5.1 Market Overview
- 13.5.2 Hospitals
- 13.5.3 Clinics
- 13.5.4 ASC's
- 13.5.5 Others
- 14 EU-4 and United Kingdom Giant Cell Arteritis Treatment Market (2017-2032)
- 14.1 EU-4 and United Kingdom Giant Cell Arteritis Treatment Market Historical Value (2017-2023)
- 14.2 EU-4 and United Kingdom Giant Cell Arteritis Treatment Market Forecast Value (2024-2032)
- 14.3 EU-4 and United Kingdom Giant Cell Arteritis Treatment Market (2017-2032) by Treatment Type
- 14.3.1 Market Overview
- 14.3.2 Medication
- 14.3.2.1 Corticosteroid Therapy
- 14.3.2.2 Immunosuppressive Agents
- 14.3.2.3 Anticoagulants
- 14.3.2.4 Monoclonal antibodies
- 14.3.3 Surgery
- 14.4 EU-4 and United Kingdom Giant Cell Arteritis Treatment Market (2017-2032) by Route of Administration
- 14.4.1 Market Overview
- 14.4.2 Oral
- 14.4.3 Intravenous
- 14.4.4 Subcutaneous
- 14.4.5 Others
- 14.5 EU-4 and United Kingdom Giant Cell Arteritis Treatment Market (2017-2032) by End Use
- 14.5.1 Market Overview

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 14.5.2□Hospitals
- 14.5.3□Clinics
- 14.5.4□ASC's
- 14.5.5□Others
- 15□Japan Giant Cell Arteritis Treatment Market
- 15.1□Japan Giant Cell Arteritis Treatment Market Historical Value (2017-2023)
- 15.2□Japan Giant Cell Arteritis Treatment Market Forecast Value (2024-2032)
- 15.3□Japan Giant Cell Arteritis Treatment Market (2017-2032) by Treatment Type
- 15.3.1□Market Overview
- 15.3.2□Medication
- 15.3.2.1□Corticosteroid Therapy
- 15.3.2.2□Immunosuppressive Agents
- 15.3.2.3□Anticoagulants
- 15.3.2.4□Monoclonal antibodies
- 15.3.3□Surgery
- 15.4□Japan Giant Cell Arteritis Treatment Market (2017-2032) by Route of Administration
- 15.4.1□Market Overview
- 15.4.2□Oral
- 15.4.3□Intravenous
- 15.4.4□Subcutaneous
- 15.4.5□Others
- 15.5□Japan Giant Cell Arteritis Treatment Market (2017-2032) by End Use
- 15.5.1□Market Overview
- 15.5.2□Hospitals
- 15.5.3□Clinics
- 15.5.4□ASC's
- 15.5.5□Others
- 16□India Giant Cell Arteritis Treatment Market
- 16.1□India Giant Cell Arteritis Treatment Market (2017-2032) Historical Value (2017-2023)
- 16.2□India Giant Cell Arteritis Treatment Market (2017-2032) Forecast Value (2024-2032)
- 16.3□India Giant Cell Arteritis Treatment Market (2017-2032) by Treatment Type
- 16.3.1□Market Overview
- 16.3.2□Medication
- 16.3.2.1□Corticosteroid Therapy
- 16.3.2.2□Immunosuppressive Agents
- 16.3.2.3□Anticoagulants
- 16.3.2.4□Monoclonal antibodies
- 16.3.3□Surgery
- 16.4□India Giant Cell Arteritis Treatment Market (2017-2032) by Route of Administration
- 16.4.1□Market Overview
- 16.4.2□Oral
- 16.4.3□Intravenous
- 16.4.4□Subcutaneous
- 16.4.5□Others
- 16.5□India Giant Cell Arteritis Treatment Market (2017-2032) by End User
- 16.5.1□Market Overview
- 16.5.2□Hospitals

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 16.5.3 Clinics
- 16.5.4 ASC's
- 16.5.5 Others
- 17 Regulatory Framework
- 17.1 Regulatory Overview
- 17.1.1 US FDA
- 17.1.2 EU EMA
- 17.1.3 Japan PMDA
- 17.1.4 Others
- 18 Patent Analysis
- 18.1 Analysis by Type of Patent
- 18.2 Analysis by Publication Year
- 18.3 Analysis by Issuing Authority
- 18.4 Analysis by Patent Age
- 18.5 Analysis by CPC Analysis
- 18.6 Analysis by Patent Valuation
- 18.7 Analysis by Key Players
- 19 Grants Analysis
- 19.1 Analysis by Year
- 19.2 Analysis by Amount Awarded
- 19.3 Analysis by Issuing Authority
- 19.4 Analysis by Grant Application
- 19.5 Analysis by Funding Institute
- 19.6 Analysis by NIH Departments
- 19.7 Analysis by Recipient Organization
- 20 Clinical Trials Analysis
- 20.1 Analysis by Trial Registration Year
- 20.2 Analysis by Trial Status
- 20.3 Analysis by Trial Phase
- 20.4 Analysis by Therapeutic Area
- 20.5 Analysis by Geography
- 21 Funding and Investment Analysis
- 21.1 Analysis by Funding Instances
- 21.2 Analysis by Type of Funding
- 21.3 Analysis by Funding Amount
- 21.4 Analysis by Leading Players
- 21.5 Analysis by Leading Investors
- 21.6 Analysis by Geography
- 22 Partnership and Collaborations Analysis
- 22.1 Analysis by Partnership Instances
- 22.2 Analysis by Type of Partnership
- 22.3 Analysis by Leading Players
- 22.4 Analysis by Geography
- 23 Supplier Landscape
- 23.1 Market Share by Top 5 Companies
- 23.2 F. Hoffmann-La Roche Ltd.
- 23.2.1 Financial Analysis

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

23.2.2□Product Portfolio
23.2.3□Demographic Reach and Achievements
23.2.4□Mergers and Acquisitions
23.2.5□Certifications
23.3□ Tianjin Tianyao Pharmaceutical Co.
23.3.1□Financial Analysis
23.3.2□Product Portfolio
23.3.3□Demographic Reach and Achievements
23.3.4□Mergers and Acquisitions
23.3.5□Certifications
23.4□Teva Pharmaceutical Industries Ltd.
23.4.1□Financial Analysis
23.4.2□Product Portfolio
23.4.3□Demographic Reach and Achievements
23.4.4□Mergers and Acquisitions
23.4.5□Certifications
23.5□GlaxoSmithKline
23.5.1□Financial Analysis
23.5.2□Product Portfolio
23.5.3□Demographic Reach and Achievements
23.5.4□Mergers and Acquisitions
23.5.5□Certifications
23.6□Pfizer Inc
23.6.1□Financial Analysis
23.6.2□Product Portfolio
23.6.3□Demographic Reach and Achievements
23.6.4□Mergers and Acquisitions
23.6.5□Certifications
23.7□Novartis
23.7.1□Financial Analysis
23.7.2□Product Portfolio
23.7.3□Demographic Reach and Achievements
23.7.4□Mergers and Acquisitions
23.7.5□Certifications
23.8□AstraZeneca
23.8.1□Financial Analysis
23.8.2□Product Portfolio
23.8.3□Demographic Reach and Achievements
23.8.4□Mergers and Acquisitions
23.8.5□Certifications
23.9□Merck & Co., Inc.
23.9.1□Financial Analysis
23.9.2□Product Portfolio
23.9.3□Demographic Reach and Achievements
23.9.4□Mergers and Acquisitions
23.9.5□Certifications
23.10□Sanofi S.A.

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 23.10.1 Financial Analysis
- 23.10.2 Product Portfolio
- 23.10.3 Demographic Reach and Achievements
- 23.10.4 Mergers and Acquisitions
- 23.10.5 Certifications
- 23.11 Astellas Pharma, Inc.
- 23.11.1 Financial Analysis
- 23.11.2 Product Portfolio
- 23.11.3 Demographic Reach and Achievements
- 23.11.4 Mergers and Acquisitions
- 23.11.5 Certifications
- 24 Giant Cell Arteritis Treatment Treatment Drugs - Distribution Model (Additional Insight)
- 24.1 Overview
- 24.2 Potential Distributors
- 24.3 Key Parameters for Distribution Partner Assessment
- 25 Key Opinion Leaders (KOL) Insights (Additional Insight)
- 26 Payment Methods (Additional Insight)
- 26.1 Government Funded
- 26.2 Private Insurance
- 26.3 Out-of-Pocket

*Additional insights provided are customisable as per client requirements.

* The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.

*The supplier list is not exhaustive. Moreover, we can provide analysis of companies as per custom requests.

□

Giant Cell Arteritis Treatment Market Report and Forecast 2024-2032

Market Report | 2024-09-30 | 250 pages | EMR Inc.

To place an Order with Scotts International:

- ☐ - Print this form
- ☐ - Complete the relevant blank fields and sign
- ☐ - Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User License	\$4999.00
	Five User License	\$5999.00
	Corporate License	\$6999.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

☐ ** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2025-05-05"/>
		Signature	<input type="text"/>

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com